Document:

Filed by Automated Filing Services Inc. (604) 609-0244 - Response Biomedical Corp. - Exhibit 4.7

          This CONSULTING
  AGREEMENT effective March 10, 2003

	BETWEEN:	RESPONSE BIOMEDICAL CORP.,
        a company incorporated in the Province of British Columbia and having
        an office at 8855 Northbrook Court, Burnaby, British Columbia V5J 5J1

	 	 
	 	(“Response”)
	 	 
	AND:	REED SIMMONS, of 19808 98th
      Ave SE, Snohomish, Washington, 98296
	 	 
	 	(the “Consultant”)

WITNESSES THAT WHEREAS:

 Response is involved in the research and commercialization
  of cost-effective and market-driven point-of-care testing systems; 

 The Consultant has certain skills and expertise which Response
  wishes to engage; and 

 The Consultant is an independent contractor, engaged pursuant
  to a contract for services, and not an employee of Response; 

 THEREFORE in consideration of the recitals, the following
  representations and covenants and the payment of one dollar made by each party
  to the other, the receipt and sufficiency of which is acknowledged by each party,
  the parties agree on the following terms:

	1.	 ENGAGEMENT AND DURATION 
	 	 
	1.1.	Response hereby engages the services of the Consultant as “Vice
      President, Manufacturing” and the Consultant hereby accepts such
      engagements and agrees to perform the services to the best of his ability
      and in accordance with the terms and conditions of this Agreement. 
	 	 
	1.2. 	Response shall engage the Consultant commencing on March 10, 2003 and
      terminating on April 30, 2003 (the “Termination Date”). 
	 	 
	1.3.	The term of this Agreement may be extended with the written mutual agreement
      of the parties at any time. 
	 	 
	2. 	DUTIES 
	 	 
	2.1. 	The Consultant shall, pursuant to this Agreement, perform such duties
      as requested from time to time by the Executive Vice-President of Response.
    
	 	 
	2.3. 	The Consultant shall report directly to the Executive Vice-President of
      Response. Upon the agreement of the Consultant, he may also report to such
      other person(s) as the Executive Vice-President of Response shall direct
      from time to time. 
	 	 
	2.4. 	The Consultant will, subject to the terms of this Agreement, comply promptly
      and faithfully with Response’s reasonable instructions, directions,
      requests, rules and regulations and commit sufficient time to reasonably
      ensure that the Company meets its corporate objectives. Notwithstanding
      the foregoing, the Consultant agrees to be on-site at the premises of Response
      at least two days per week. 

1 

 

	3.	REMUNERATION AND BENEFITS

	 	 
	3.1 	FEES

	 	 
	3.1.1 	For services provided by
        the Consultant from March 10, 2003 until the Termination Date, the Consultant
        will be paid a monthly retainer for services in the amount of US$6,500.
        The Consultant will present an invoice to Response on or about the end
        of each calendar month until the expiration of this Agreement or its prior
        termination, and Response will satisfy the account as presented by payment
        to the Consultant within 7 days of the presentation of the account.

	 	 
	3.1.2 	In addition to the fees
        above, the Consultant shall be entitled to participate in any bonus incentive
        plan enacted by the Company.

	 	 
	3.2.	OPTIONS

	 	 
	3.2.1 	As further consideration
        of the services provided by the Consultant, the Company shall grant the
        Consultant a stock option in accordance with policies of the Canadian
        Venture Stock Exchange and Response’s Stock Option Plan as follows:

	 	 
	 	(a)
	an option granted May 1, 2003 to purchase
        up to a total of 100,000 common shares of Response at a price of
        $0.50 and set to expire on April 30, 2005 and vesting 25% upon grant,
        and an additional 25% vesting in each of the three subsequent 6 month
        periods.

	 	 
	3.3. 	REIMBURSEMENT OF EXPENSES

	 	 
	3.3.1. 	Within 30 days of the presentation
        of receipts to Response by the Consultant, Response shall reimburse the
        Consultant for all reasonable expenses incurred by the Consultant in the
        performance of his duties pursuant to this Agreement.

	 	 
	4.	RESTRICTIVE COVENANTS

	 	 
	4.1. 	NON-COMPETITION

	 	 
	4.1.1.	During the term of this
        Agreement and for twelve months following the termination or expiration
        of this Agreement, the Consultant shall not:

	 	 	 
	 	(a)
	own or have any interest directly in;

	 	 	 
	 	(b)
	act as an officer, director, agent Consultant
        or consultant of; 

	 	 	 
	 	(c)
	assist in any way or in any capacity,
        any person, firm, association, partnership, corporation or other entity
        which is focused on the research and commercialization of quantitative
        lateral flow point-of-care testing systems for human, veterinary, food
        safety or environmental markets, or is otherwise engaged in a business
        that is substantially similar to and/or competes with the business then
        engaged in by Response (the “Competitive Entity”), in any province
        of Canada or any state of the United States where Response engages in
        such business.

	 	 
	4.1.2. 	The restriction set out
        in subparagraph 4.1.1(a) above shall not apply to the Consultant’s
        ownership of less than ten percent (10%) of the securities of any Competitive
        Entity.

 2 

 

	4.1.3. 	The Consultant acknowledges
        that the restrictions contained in this Section 4.0 are reasonable; however,
        in the event that any court should determine that any of the restrictive
        covenants contained in subparagraph 4.1.1 or 4.1.2 of this Agreement,
        or any part thereof, are unenforceable because of the duration of such
        provision or the area covered thereby, such court shall have the power
        to reduce the duration or area of such provision and, in its reduced form,
        such provision shall then be enforceable and shall be enforced.

	 	 
	4.2. 	CONFIDENTIALITY

	 	 
	4.2.1. 	The term “Confidential
        Information” means any and all information concerning any aspect
        of Response not generally known to persons other than those associated
        with Response including, but not limited to, clinical data, concepts,
        processes and techniques, trade secrets, business strategies and financial
        information. Response may disclose, in writing or orally, to the Consultant
        certain Confidential Information. These disclosures will be directed primarily
        to the subject of research and commercialization of quantitative lateral
        flow point-of-care testing systems for human, veterinary, food safety
        and environmental markets, but may also include proprietary and Confidential
        Information relating generally to development of RAMP.

	 	 
	4.2.2	The Consultant acknowledges
        and agrees that the Confidential Information is disclosed to the Consultant
        in the strictest confidence and any Confidential Information disclosed
        to the Consultant in any form whatsoever is and shall be considered confidential
        and proprietary information of Response.

	 	 
	4.2.3. 	Except as authorized by
        Response, the Consultant will not:

	 	 
	 	(a)
	duplicate, transfer or disclose nor
        allow any other person to duplicate, transfer or disclose any of the Confidential
        Information;

	 	 	 
	 	(b)
	use the Confidential Information without
        the prior written consent of Response; or

	 	 	 
	 	(c)
	incorporate, in the whole or in part,
        within any domestic or foreign patent application any proprietary or Confidential
        Information disclosed by Response.

	 	 
	4.2.4. 	The Consultant will safeguard
        all Confidential Information at all times so that it is not exposed to
        or used by unauthorized person(s), and will exercise at least the same
        degree of care used to protect the Consultant’s own Confidential
        Information.

	 	 
	4.2.5.	 Any and all notes, diagrams,
        reports, notebook pages, memoranda, and like materials and chemical, and
        biological materials received from Response and any copies or excerpts
        thereof containing proprietary or Confidential Information will remain
        the property of Response and will, upon the request of Response, be promptly
        returned to Response.

	 	 
	4.2.6.	The restrictive obligations
        set forth above shall not apply to the disclosure or use of any information
        which:

	 	 
	 	(a)
	is or later becomes publicly known under
        circumstances involving no breach of this Agreement by the Consultant;

	 	 	 
	 	(b)
	is already known to the Consultant at
        the time of receipt of the Confidential Information; or

	 	 	 
	 	(c)
	is lawfully made available to the Consultant
        by a third party.

	 	 	 
	4.2.7. 	No patent rights or licenses
        are granted by this Agreement. The disclosure of Confidential Information
        under this Agreement shall not result in any obligation for either party
        to grant any rights in its patent rights or Confidential Information,
        and no other obligations of any kind are assumed by or implied against
        either party, except for as stated in this Agreement.

 3 

 

	4.2.8. 	The provisions of Section
        4.2 shall survive the termination of this Agreement.

	 	 
	4.3. 	DELIVERY OF RECORDS

	 	 
	4.3.1. 	Upon the termination of
        the Consultant’s engagement with the Company, the Consultant will
        deliver to the Company all books, records, lists, brochures and other
        property belonging to the Company or developed in connection with the
        business of the Company.

	 	 
	5.	OWNERSHIP OF WORK
        PRODUCT

	 	 
	5.1. 	Any and all know-how, ideas,
        discoveries, inventions, improvements, formula, methods, processes, systems,
        plans and any other knowledge or information of a technical or scientific
        nature or of a business nature pertinent to Response’s scientific
        or business interests whether protectable as industrial or intellectual
        property right or not, which the Consultant may conceive develop or acquire
        whether solely or jointly with any other party in furtherance of the engagement
        with Response will be the sole and exclusive property of Response; however,
        Response agrees to name the Consultant as the inventor on any patent applications
        made as a result of work performed by him under this Agreement, provided
        that all such patent applications are assigned to Response.

	 	 
	6.	TERMINATION

        

	 	 	 
	6.1.	Response may terminate the Consultant’s
      engagement under this Agreement:
	 	 	 
	 	(a)
	at any time if there is a material breach
        or default of any term of this Agreement by the Consultant if such material
        breach or default has not been remedied to the satisfaction of Response
        within 1 working day after written notice of the material breach or default
        has been delivered by Response to the Consultant; and

	 	 	 
	 	(b)
	at any time by providing 30 days notice
        in writing.

	 	 	 
	6.2.	 The Consultant may terminate
        its obligations under this Agreement:

	 	 	 
	 	(a)
	at any time by providing 30 days notice
        in writing; and

	 	 	 
	 	(b)
	upon a material breach or default of
        any term of this Agreement by Response if such material breach or default
        has not been remedied to the satisfaction of the Consultant within fifteen
        (15) working days after written notice of the material breach or default
        has been delivered by the Consultant to Response.

	 	 
	6.3.	 The rights of Response
        and the Consultant under this section 6.0 are in addition to and not in
        derogation of any other remedies which may be available to the Company
        or the Consultant at law or in equity.

	 	 
	6.4 	In the event of any dispute
        arising with respect to any matter relating to this Agreement, the matter
        in dispute shall be referred to a single arbitrator under the Commercial
        Arbitration Act then in effect in British Columbia

	 	 
	7.	WAIVER

	 	 
	7.1. 	No consent or waiver, express
        or implied, by any party to this Agreement of any breach or default by
        the other party in the performance of its obligations under this Agreement
        or of any of the terms, covenants or conditions of this Agreement shall
        be deemed or construed to be a consent or waiver of any subsequent or

 4 

	 	continuing breach or default in such party’s
        performance or in the terms, covenants and conditions of this Agreement.
        The failure of any party to this Agreement to assert any claim in a timely
        fashion for any of its rights or remedies under this Agreement shall not
        be construed as a waiver of any such claim and shall not serve to modify,
        alter or restrict any such party’s right to assert such claim at
        any time thereafter. 

	 	 
	8. 	NOTICES 

	 	 
	8.1. 	Any notice relating to this Agreement or required
        or permitted to be given in accordance with this Agreement shall be in
        writing and shall be personally delivered or mailed by registered mail,
        postage prepaid to the address of the parties set out on the first page
        of this Agreement, any notice shall be deemed to have been received if
        delivered, when delivered, and if mailed, on the fifth day (excluding
        Saturdays, Sundays and holidays) after the mailing thereof. If normal
        mail service is interrupted by strike, slowdown, force majeure or other
        cause, a notice sent by registered mail will not be deemed to be received
        until actually received and the party sending the notice shall utilize
        any other services which have not been so interrupted or shall deliver
        such notice in order to ensure prompt receipt thereof. 

	 	 
	8.2. 	Each party to this Agreement may change its address
        for the purpose of this section by giving written notice of such change
        in the manner provided for in section 8.1. 

	 	 
	9. 	APPLICABLE LAW 

	 	 
	9.1. 	This Agreement shall be governed by and construed
        in accordance with the laws of the province of British Columbia and the
        federal laws of Canada applicable therein, which shall be deemed to be
        the proper law hereof. The parties hereto hereby submit to the jurisdiction
        of the courts of British Columbia. 

	 	 
	10. 	SEVERABILITY 

	 	 
	10.1.	If any provision of this Agreement for any reason
        is declared invalid, such declaration shall not affect the validity of
        any remaining portion of the Agreement, which remaining portion shall
        remain in full force and effect as if this Agreement had been executed
        with the invalid portion thereof eliminated and is hereby declared the
        intention of the parties that they would have executed the remaining portions
        of this Agreement without including any such part, parts portion which
        may, for any reason, be hereafter declared invalid. 

	 	 
	11. 	ENTIRE AGREEMENT 

	 	 
	11.1.	Other than the stock option agreement referred to
        in Section 3.2.1, this Agreement constitutes the entire agreement between
        the parties hereto. There are no representations or warranties, express
        or implied, statutory or otherwise other than set forth in this Agreement
        and there are no agreements collateral hereto other than as are expressly
        set forth or referred to herein. The Agreement cannot be amended or supplemented
        except by a written agreement executed by both parties hereto. 

	 	 
	12. 	NON-ASSIGNABILITY 

	 	 
	12.1. 	This Agreement shall not be assigned by either party
        to this Agreement without the prior written consent of the other party
        to this Agreement. 

	 	 
	13. 	BURDEN AND BENEFIT 

	 	 
	13.1. 	This Agreement shall enure to the benefit of and
        be binding upon the parties hereto and their respective heirs, executors,
        administrators, successors and permitted assigns. 

5 

	14. 	TIME 
	 	 
	14.1.	Time is of the essence of this Agreement. 

IN WITNESS WHEREOF the Subscriber has duly executed this subscription
  as of the date set out on the first page of this Agreement. 

	RESPONSE BIOMEDICAL CORP.	 	REED SIMMONS
	 	 	 
	 	 	 
	"William Radvak"	 	"Reed Simmons"
	Authorized Signatory	 	 

 6Filed by Automated Filing Services Inc. (604) 609-0244 - Response Biomedical Corp. - Exhibit 4.8

MANAGEMENT CONSULTING AGREEMENT

           This
  Management Consulting Agreement is made as of July 7, 2003. between
  Response 13iomedieai Corp. ("Response" or the "Company") and Katan Associates,
  Inc. (the "Consultant").

	1.	Engagement - Response
        hereby agrees to engage the services of the Consultant and the Consultant
        hereby accepts such engagement by the Company to perform consulting services
        for the Company on the terms contained herein.

	 	 
	2.	Duties - The Consultant
        shall render the services described in the Consultant's letter dated July
        7, 2003 and attached as Schedule A hereto, and such other matters as may
        be requested by the CEO of the Company from time to time.

	 	 
	3.	Term and Termination
        - This Agreement shall commence on Aug 1, 2003 and expire June 30, 2005
        provided, however, that after September 30, 2003 either party may terminate
        this agreement upon 30 days written notice delivered to the other party,
        which termination may be with or without cause and for any reason whatsoever.

	 	 
	4.  	Remuneration.

	 	 
	 	(a)
	Fees.    For
        services provided, the Company agrees to pay the Consultant a retainer
        of US$5,000 per month for the term of the Agreement.

	 	 	 
	 	(b)
	Options. As further consideration
        of the services provided hereunder, the Company shall grant the Consultant
        a stock option (the "Consultant's Stock Option") to purchase up to 200,000
        common shares of Response, exercisable at $0.50 in accordance with policies
        of the TSX Venture Exchange and the Company's Stock Option Plan. The options
        shall vest as follows: 25% upon grant, and an additional 25% in each of
        the three subsequent 6 month periods. Additionally, the vesting of the
        Consultant's Stock Option will be conditional upon Response successfully
        completing either an equity financing or partnership transaction as outlined
        in paragraphs 3(d) and 3(e) below. The shares underlying such options
        shall have registration rights and other standard provisions.

	 	 	 
	 	(c)
	Reimbursement of Expenses. The
        Company shall reimburse the Consultant for all reasonable and properly
        documented expenses related to this engagement. Any expenses in excess
        of $100 are to be approved in writing in advance by the CEO of Company.

	 	 	 
	 	(d)

          
	Financing Success Fees. In the
        event that the Company completes an equity financing with an investor
        introduced by the Consultant and pre-qualified by Response, Response shall
        pay the Consultant a success fee equal to 5% of the gross proceeds provided
        by each investor introduced to Response by the Consultant. The success
        fee is payable within 5 business

 

	 	 	days of Response closing the financing.
        In the situation where an investor's proceeds are received by Response
        in trenches, the Consultant's fee shall be payable on the same terms at
        the time each tranche is received by Response, The terms of this paragraph
        will be further amplified by a formal finder's fee agreement executed
        by Response and the Consultant prior to an equity financing. The success
        fee will only be payable with respect to prospective investors introduced
        by the Consultant and pre-qualified by Response (the "Named Investors").
        All Named Investors shall be identified and attached as a schedule to
        the finder's fee agreement. It is understood by both Response and the
        Consultant that in the event a financing is conducted through a third
        party investment banking firm, underwriter or agent (the "Agent") introduced
        by the Consultant to Response, then Response will negotiate an aggregate
        commission or finder's fee payable to the Agent (the "Agent's Fee") for
        the financing and the Consultant's success fee will be payable out of
        the Agent's Fee.

	 	 	 
	 	(e)
   	Partner Finder's Fees. In the
        event that the Company completes a partnering transaction with a prospective
        partner introduced by the Consultant and pre-qualified by Response ("Named
        Partner") and where licensing fees are paid by the Named Partner, Response
        shall pay the Consultant a partner finder's fee (the "Partner's Fee")
        equal to 5% of the amount of the licensing fee within 5 business days
        of Response receiving the funds. The terms of this paragraph will be further
        amplified by a formal Partner's Fee agreement executed by Response and
        the Consultant prior to initiating the partnering transaction. All Named
        Partners shall be identified and attached as a schedule to the Partner's
        Fee agreement.

	 	 	 
	5. 	Restrictive Covenants.
	 	 	 
	 	(a)	Non-Compete. The Consultant agrees
        not to render any services during the term of this Agreement to any company
        or person engaged in a business which is competitive to the Company.

	 	 	 
	 	(b)
   	Confidentiality. The Consultant
        shall keep in confidence and shall not disclose or make available to third
        parties or make any use of any information or documents relating to his/her
        services under this Agreement or to the product, methods of manufacture,
        trade secrets, processes, business or affairs of the Company (other than
        information in the public domain through no fault of the Consultant),
        except with the prior written consent of the Company or to the extent
        necessary in performing tasks assigned to the Consultant by the
        Company. Upon termination of this Agreement, the Consultant will return
        to the Company all documents and other materials related to the services
        provided hereunder or furnished to the Consultant by the Company. The
        Consultant's obligations under this Section 4(b) shall survive termination
        of this Agreement.

2

 

	 	(c)
	Delivery of Records. Upon the
        termination of the Consultant's engagement with the Company, the Consultant
        will deliver to the Company all books, records, lists, brochures and other
        property belonging to the Company or developed in connection with the
        business of the Company.

	 	 
	4.	Ownership of Work Product
        - Any and all know-how, ideas, discoveries, inventions, improvements,
        4. formula, methods, processes, systems, plans and any other knowledge
        or information of a technical or scientific nature or of a business nature
        pertinent to the Company's scientific or business interests whether protectable
        as industrial or intellectual property right or not, which the Consultant
        may conceive develop or acquire whether solely or jointly with any other
        party in furtherance of the engagement with the Company will be the sole
        and exclusive property of the Company; however, the Company agrees to
        name the Consultant as the inventor on any patent applications made as
        a result of work performed by him under this Agreement, provided that
        all such patent applications are assigned to Response.

	 	 
	5.	Independent Contractor
        - The Consultant's relationship with the Company shall be that of
        an independent contractor and not that of an employee. The Consultant
        will not be eligible for any employee benefits, nor will the Company make
        any deductions from the Consultant's fees for taxes, which shall be the
        Consultant's responsibility. The Consultant shall have no authority to
        enter into contracts which bind the Company or create obligations on the
        part of the Company without the express prior authorization of the Company.

	 	 
	6.	Effect of Waiver
        - The waiver by either party of a breach of any provision of this Agreement
        shall not operate or be construed as a waiver of any other provision or
        any subsequent breach of the same provision thereof.

	 	 
	7.	Indemnification -
        Company agrees to indemnify, defend and hold harmless Consultant from
        and against any loss, damage, expense and liability that Company may incur
        as a result of matters referenced in Sections 1, 2, and 3, except that
        the indemnification shall not apply where it has been determined that
        die Consultant, in the performance of his duties herein, has acted unlawfully
        or with gross negligence.

	 	 
	8.	Severability - If
        any portion of this Agreement is held, by a court of competent jurisdiction,
        to conflict with any Federal, state or local law, such portion or portions
        of this Agreement are hereby declared to be of no force and effect in
        such jurisdiction and this Agreement shall otherwise remain in full force
        and effect and be construed as if such portion had not been included herein.

3

 

	9. 	Miscellaneous
	 	 	 
	 	(a)	Section headings are employed in this
        Agreement for reference purposes only and shall not affect the interpretation
        or meaning of this Agreement.

	 	 	 
	 	(b)	This Agreement shall be governed by
        and construed in accordance with the internal laws of Florida.

	 	 	 
	 	(c)	This Agreement may be signed in counterparts,
        each of which shall be an original and both of which shall constitute
        one instrument.

IN WITNESS WHEREOF, the parties hereto have executed this Agreement as of the
  day and year first Above written.

	Response Biomedical Corp.	Katan Associates,
	/s/ Bill Radvak                     

      Bill Radvak, President and CEO	

      

      /s/ Seth Yakatan                       

      Seth Yakatan, Partner 

 KATAN ASSOCIATES, Inc 

  1620 Alton Road, #310  

  Miami Beach, FL 33139 

July 7, 2003

 Response Biomedical Corp.

  Mr. Bill Radvak, President and CEO

  8855 Northbrook Court 

  Burnaby, British Columbia 

  Canada, V57 5J1

 Dear Bill:

 This letter is to act as Exhibit A to the Management Consulting
  Agreement dated July 1, 2003 (the "Agreement") between Katan Associates, Inc.
  (" Katan") and Response Biomedical Corp. ("Response" or the "Company"). Under
  the terms of the Agreement, Katan shall, at the request of the CEO of the Company,
  render management advisory services, including but not limited to the following:

	1.	Assist senior management
        to develop and execute a financing strategy for the Company focused on
        raising sufficient capital to implement its business plan and enhancing
        overall market capitalization through an increased share price.

        Action Items:

	 	 	 
	 	a.
	Recommend a program to increase visibility
        and validation of the Company throughout the industry.

	 	 	 
	 	b.
	Recommend specific industry related
        financial functions for the Company to attend and facilitate/support such
        attendance.

	 	 	 
	 	c.
	Provide introductions to industry partners
        and investors,

	 	 	 
	 	d.
	Provide, advice on the structure of
        a US and/or European based financing and facilitate placement thereof.

	 	 	 
	 	e.
	Recommend a program to list the Company
        on the AMEX, NASDAQ or OTC bulletin board.

	 	 
	2.	 Assist Senior
        Management to develop and implement a partnering
        strategy for the Company that maximizes value by: (i) having a partner
        assume development costs for new products; (ii) attracting up-front licensing
        fees- and (iii) earning compensation for the Company based on sales revenue,

      Action Items;

	 	 	 
	 	a.
	identify key Katan contacts within potential
        partner organizations, make appropriate introductions and manage the negotiating
        process to maximize the value to the Company of my ensuing partnership.

	 	 	 
	 	b.	assist management to assess and execute on potential partnering
      opportunities for the Company's RAMP technology including, but not limited
      to, sales and marketing of existing RAMP products; in-licensing/out-licensing
      of technology. 
	 	 	 
	 	c.	 represent the Company in its negotiations with new out-licensing
      partners where appropriate. 
	 	 	 
	 	d. 
	assist in determining a valuation for
        specific partnering transactions as required.

 July 7, 2003 

  Response Biomedical Corporation 

  Mr. Bill Radvak, President and CEO 

  

 

Please attach this to the accompanying Management Consulting Agreement. 

Yours sincerely,

/s/ Seth Yakatan                       

  Seth Yakatan, Partner 

Seth Yakatan 

  Partner

Source: [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00060-of-00352.parquet"}, [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00060-of-00352.parquet"}]]